GREY:ATBPF - Post by User
Comment by
Jefferam1on Nov 16, 2017 3:58pm
124 Views
Post# 26979467
RE:RE:RE:Who are their main competitors?
RE:RE:RE:Who are their main competitors? Could you see this stock completely tank if phase 2 doesn't go good? Absolutely.
This stock has a 15 MM market cap, they bought Citagenix for 10MM some would argue that it should retain that value, I'm not convinced.
I believe their future rest on the results of the clinical trials.
What does ATE have going for itself? They have done lots of animal studies to prove it works. They have done a small human trial to see it being effective. Their only negative is the study where they admittedly underestimated its efficacy and gave too high dosage on the upper end of the phase dosing testing. Had they given the equivalent dosage of naproxen, it wouldn't have been good for the person as well. They have been able to study the results and are able to keep it to a more modest range as the drug is much more effective than initially thought. It also didn't help that the person with the adverse effect lied on his application and had previous hepatitis issues.
Is this stock risky? It's trading at $0.09, it's a penny stock, of course it's risky. This is not a blue chip, but the upside is HUGE. The main reason why I'm invested is that I feel management has done sufficient testing and research to prove the risk is small. Much smaller than comparable other penny stocks in my opinion.